Staphylococcus Aureus Bacteremia Market to Accelerate Substantially During the Forecast Period | Key Companies – Basilea Pharma, NovaDigm Therapeutics, iNtRON, and Baxter - Digital Journal

"Delveinsight Business Research LLP"

DelveInsight's "Staphylococcus Aureus Bacteremia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Staphylococcus Aureus Bacteremia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Staphylococcus Aureus Bacteremia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Staphylococcus Aureus Bacteremia: An Overview

Staphylococcus aureus (S. aureus) is a gram-positive bacterium and a causative agent of healthcare-associated infections from both community-acquired and hospital-acquired bacteremia. It causes a wide range of diseases from mild to life-threatening conditions and is a leading cause of bacteremia and infective endocarditis (IE). It can cause multiple infections, such as lung (pneumonia, influenza-associated), skin (moderately severe, rarely necrotizing fasciitis), bone (osteomyelitis), bloodstream (bacteremia), specific toxin-related diseases (toxic shock syndrome, foodborne illness), and others.

S. aureus Bacteremia (SAB) is among the most prevalent and difficult to treat the condition with higher morbidity and mortality. S. aureus most often spreads by contaminated hands. The breaching of the skin and mucous membranes may give access to S. aureus to enter underlying tissues or the bloodstream.

Staphylococcus Aureus Bacteremia Market Key Facts

• S. aureus bacteremia is estimated with an incidence rate ranging from 20 to 50 cases per 100,000 population per year (Van Hal et al. 2012). Even though overall rates of SAB may have stabilized, the incidence of MRSA bacteremia has increased dramatically in recent years in both the US and Europe.

• In the study of 247 evaluable adult patients with S. aureus bacteremia, the episodes of bacteremia were classified according to acquisition type, in which 23.5% were nosocomial (N-SAB), 58.7% were healthcare-associated (HCA-SAB), and 17.8% were community-acquired (CA-SAB) (Atrouni et al., 2009).

• England reported 18,403 SAB cases or an incidence of 37 SAB per 100,000 inhabitants from April 2002 to March 2003 through the EARSS surveillance scheme.

• According to the literature review, in the US, invasive MRSA infections occur in approximately 94,000 people each year (Klevens et al. 2007).

Staphylococcus Aureus Bacteremia Market

Staphylococcus Aureus Bacteremia market size is expected to increase during the forecast period owing to the increasing incident population in the 7MM. Over the past years, increased antibiotic resistance, and higher numbers of patients with immunocompromised status have led to sharp increases in the incidence and mortality of SAB.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Staphylococcus Aureus Bacteremia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Staphylococcus Aureus Bacteremia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Staphylococcus Aureus Bacteremia Epidemiology

In recent years, the incidence of S. aureus bacteremia and its complications has increased sharply due to the increased frequency of invasive procedures, immunocompromised patients, and increased resistance of S. aureus strains to available antibiotics.

The emergence and spread of methicillin-resistant S. aureus (MRSA) strains with multidrug-resistant in hospitals and subsequently in the community resulted in significant mortality and morbidity.

The epidemiology section covers insights about the historical and current Staphylococcus Aureus Bacteremia patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Staphylococcus Aureus Bacteremia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Staphylococcus Aureus Bacteremia market or expected to get launched in the market during the study period. The analysis covers Staphylococcus Aureus Bacteremia market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Staphylococcus Aureus Bacteremia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market

Some of the key companies in the Staphylococcus Aureus Bacteremia Market include:

• Basilea Pharmaceutica

• NovaDigm Therapeutics

• iNtRON Biotechnology

• Baxter

And many others.

Staphylococcus Aureus Bacteremia Therapies covered in the report include:

• Ceftobiprole

• NDV-3A

• TonaBACASE

• Oxacillin

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-  https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Staphylococcus Aureus Bacteremia Competitive Intelligence Analysis

4. Staphylococcus Aureus Bacteremia Market Overview at a Glance

5. Staphylococcus Aureus Bacteremia Disease Background and Overview

6. Staphylococcus Aureus Bacteremia Patient Journey

7. Staphylococcus Aureus Bacteremia Epidemiology and Patient Population

8. Staphylococcus Aureus Bacteremia Treatment Algorithm, Current Treatment, and Medical Practices

9. Staphylococcus Aureus Bacteremia Unmet Needs

10. Key Endpoints of Staphylococcus Aureus Bacteremia Treatment

11. Staphylococcus Aureus Bacteremia Marketed Products

12. Staphylococcus Aureus Bacteremia Emerging Therapies

13. Staphylococcus Aureus Bacteremia Seven Major Market Analysis

14. Attribute Analysis

15. Staphylococcus Aureus Bacteremia Market Outlook (7 major markets)

16. Staphylococcus Aureus Bacteremia Access and Reimbursement Overview

17. KOL Views on the Staphylococcus Aureus Bacteremia Market.

18. Staphylococcus Aureus Bacteremia Market Drivers

19. Staphylococcus Aureus Bacteremia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market

Other Trending Healthcare Reports By DelveInsight

Bevacizumab Biosimilars Insight

DelveInsight's, "Bevacizumab Biosimilar Insight" report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Adblock test (Why?)